UNITED STATES OF AMERICA —A biotechnology initiative aimed at addressing severe pregnancy complications has secured up to $35 million in capital from the Gates Foundation. The funding deal includes an upfront investment of $20 million directed toward Cambridge-based ProFound Therapeutics. The capital injection will fund the discovery of novel biological targets and biomarkers for preeclampsia and eclampsia, two conditions that contribute significantly to global maternal morbidity and mortality but remain historically under-researched.
ProFound Therapeutics is a biotechnology firm founded in 2020 by Flagship Labs, the innovation arm of Flagship Pioneering. The company utilizes its proprietary ProFoundry platform to systematically analyze the expanded human proteome, leveraging advanced computational tools, experimental assays, and agentic artificial intelligence to identify previously undetected functional proteins and disease targets.
The investment addresses a critical gap in global healthcare research and development, where female-specific medical conditions outside of oncology receive approximately 1% of total global venture and institutional funding. By focusing on placenta and blood serum samples from affected patients, the project aims to map causal biology and build customized artificial intelligence models dedicated specifically to preeclampsia and eclampsia diagnostic and therapeutic workflows.
For the pharmaceutical and global health sectors, this financial commitment highlights a growing strategic push to integrate artificial intelligence with deep biological dataset analysis to accelerate drug discovery timelines. Successful identification of validated protein targets and diagnostic markers could open new commercial avenues for therapeutic developers while providing scalable clinical interventions in low- and middle-income regions where maternal health resources are limited.
